Eosinophilic Esophagitis: What Works, What Doesn't?

Your daily dose of the clinical news you may have missed.

Recurrent C difficile requires pulse vancomycin therapy; fecal microbiota transplant shows promise.

Upadacitinib shows promising real-world effectiveness for managing moderate-to-severe Crohn disease, even in patients with prior treatment exposure.

The goals of therapy for patients with inflammatory bowel disorder include inducing and maintaining a steroid-free remission, preventing and treating the complications of the disease, minimizing treatment toxicity, achieving mucosal healing, and enhancing quality of life.

The IL-23 inhibitor is the only drug in the class available with both subcutaneous and intravenous administration options for treatment induction, according to J&J.

The impact of food elimination diets on medication previously was unknown, according to new research presented at AAAAI 2025.